Clinical Trials Directory

Trials / Terminated

TerminatedNCT01264159

Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Hillel Yaffe Medical Center · Other Government
Sex
All
Age
Healthy volunteers
Not accepted

Summary

It is well known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedence-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

Conditions

Interventions

TypeNameDescription
DEVICELung impedence-guided therapy
OTHERUsual treatment of patients with developing acute heart failure

Timeline

Start date
2011-01-01
Primary completion
2015-01-01
Completion
2015-07-01
First posted
2010-12-21
Last updated
2020-06-11

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01264159. Inclusion in this directory is not an endorsement.

Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients (NCT01264159) · Clinical Trials Directory